China announces 'conditional' approval of Pfizer's anti-Covid pill

Paxlovid reduces deaths in those at risk of developing severe disease

• SAVE ARTICLES

  Exclusive feature for subscribers

  SUBSCRIBE or LOGIN

• SPECIAL SHARE

  Subscribers can release 5 accesses per day to Folha content

  Subscribers can release 5 accesses per day to Folha content

  Subscribers can release 5 accesses per day to Folha content

  SIGN ITorLOG IN

BEIJING | AFP

China's drug regulator said on Saturday it had given "conditional" approval to use the US-based Pfizer 's anti-Covid pill to treat adults with mild to moderate illnesses who may develop severe symptoms. .

The National Medical Devices Administration also requested that more research on the drug be carried out and sent to the entity.

Administered orally, this antiviral treatment is marketed as paxlovid and has been licensed in at least 40 countries, including the United States and Israel. The European Union has allowed its use to member countries while processing their official authorization.

Paxlovid, Pfizer's Covid drug, in production process in Italy - Pfizer/Handout/Reuters